[HIV protease inhibitors: drug interactions]

Area of Science:

• Pharmacology
• Infectious Diseases
• Virology

Background:

• HIV infection management has significantly improved due to better understanding of viral dynamics and potent antiretroviral drugs.
• Progress in treating opportunistic infections and advancements in viral load quantification have also contributed to improved outcomes.
• However, increased use of potent drugs has led to a higher potential for drug interactions.

Purpose of the Study:

• To summarize known drug interactions associated with protease inhibitors used in HIV treatment.
• To highlight the clinical implications of these interactions for combination therapy.
• To discuss the therapeutic benefits and risks of protease inhibitors in HIV management.

Main Methods:

• Review of known drug interactions with specific protease inhibitors (saquinavir, indinavir, ritonavir, nelfinavir).
• Analysis of consequences for co-administration, including contraindications and necessary dosage adjustments.
• Evaluation of clinical practice implications for selecting HIV treatment regimens.

Main Results:

• Protease inhibitors can interact with concurrent treatments due to alterations in hepatic metabolism.
• Specific drug interactions vary for each protease inhibitor, with some contraindications and others requiring dosage adjustments.
• These interactions significantly impact the choice of combination therapy in clinical practice.

Conclusions:

• Potential drug interactions necessitate careful monitoring but should not preclude the use of highly active antiretroviral drugs.
• Further studies are needed to define the value of protease inhibitor combinations and non-nucleoside reverse transcriptase inhibitor treatments.
• Increasing clinical experience will enhance understanding of drug interactions for optimal HIV management.